2C Tech Corp. Inc.
Preserving retinal cells with injectable nanoparticles
This article was originally published in Start Up
Executive Summary
2C Tech Corp. is developing a non-surgical, nanotechnology-based artificial retinal prostheses designed to overcome the limitations of current, implanted silicon chips and to operate at the cellular level over the entire retina to preserve sight. The start-up’s injectable SeeQ device converts ambient light to electrical energy. As photoreceptors are stimulated by the electrical charge, they release growth factors beneficial for retinal cell preservation.
You may also be interested in...
Artificial Retinal Devices Help The Blind To See
Worldwide rates of all diseases that cause blindness are expected to double by 2020 due to the aging population, making this an area ripe for medical device innovation. A multibillion-dollar market has been built around the surgical correction of "front of the eye" age-related vision disorders such as presbyopia, but the technological evolution in ophthalmology has now reached the back of the eye. Artificial retinal prostheses are an increasingly popular area of investigation. Start-ups hoping to enter this market face daunting R&D, clinical and regulatory hurdles, and will require significant resources. We profile three such companies in this issue: 2C Tech Corp., LambdaVision and Nano Retina.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.